PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTriclabendazole
Triclabendazole
Egaten (triclabendazole) is a small molecule pharmaceutical. Triclabendazole was first approved as Egaten on 2019-02-13. It is used to treat fascioliasis in the USA.
Download report
Favorite
Novartis Pharmaceuticals
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
Trade Name
FDA
EMA
Egaten
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triclabendazole
Tradename
Company
Number
Date
Products
EGATENNovartisN-208711 RX2019-02-13
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
egatenNew Drug Application2025-03-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
fascioliasisEFO_1001324D005211B66.3
Agency Specific
FDA
EMA
Expiration
Code
TRICLABENDAZOLE, EGATEN, NOVARTIS
2026-02-13ODE-228
2024-02-13NCE
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02B: Antitrematodals
— P02BX: Other antitrematodal agents in atc
— P02BX04: Triclabendazole
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FascioliasisD005211EFO_1001324B66.3———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTriclabendazole
INNtriclabendazole
Description
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole is an aromatic ether.
Classification
Small molecule
Drug classantithelmintics (tibendazole type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1
Identifiers
PDB—
CAS-ID68786-66-3
RxCUI—
ChEMBL IDCHEMBL1086440
ChEBI ID—
PubChem CID50248
DrugBankDB12245
UNII ID4784C8E03O (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,308 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
36 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use